Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Int Immunopharmacol ; 101(Pt A): 108292, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: covidwho-1487772

RESUMEN

Leukopenia is a common manifestation of many diseases, including global outbreak SAS-CoV-2 infection. Granulocyte-macrophage colony-stimulating factor (GM -CSF) has been proved to be effective in promoting lymphocyte regeneration, but adverse immunological effects have also emerged. This study aim to investigate the effect of GM -CSF on BCR heavy chain CDR3 repertoire while promoting lymphocyte regeneration. Cyclophosphamide (CTX) and GM -CSF were used to inhibit and stimulate bone marrow hematopoiesis, respectively. High throughput sequencing was applied to detect the characteristics of BCR CDR3 repertoire in controls, CTX group and GM -CSF group. The white blood cells (WBCs) were quickly reduced (P < 0.05) with lymphocytes decreasing causing by CTX, and the WBCs and lymphocytes returned to the level of controls after GM -CSF treatment. The diversity of BCR heavy chain CDR3 repertoire was also significantly decreased in CTX group. Although there is still a big gap from the controls, the diversity was picked up after GM -CSF treatment. The expression of IGHD01-01, IGHD02-14 and IGHJ04-01 with high-frequency usage regularly and significantly changed in three groups, and many genes with low-frequency usage lost in CTX group and did not reappear in GM -CSF group. Moreover, two shared sequences and accounted for the highest proportion in GM -CSF group have been detected in animal model of chronic lymphocytic leukemia. These results revealed that GM -CSF can partially restore changes in the BCR heavy chain CDR3 repertoire while promoting lymphocyte regeneration, but it may also lead to rearrangement, proliferation and activation of abnormal B cells, which can provide a basis for further study on the adverse immunological effects and mechanism of GM -CSF treatment.


Asunto(s)
Ciclofosfamida/efectos adversos , Factor Estimulante de Colonias de Granulocitos y Macrófagos/inmunología , Leucopenia/inmunología , Linfocitos/efectos de los fármacos , Linfocitos/inmunología , Receptores de Antígenos de Linfocitos B/efectos de los fármacos , Receptores de Antígenos de Linfocitos B/metabolismo , Animales , Regiones Determinantes de Complementariedad/efectos de los fármacos , Regiones Determinantes de Complementariedad/genética , Regiones Determinantes de Complementariedad/metabolismo , Ciclofosfamida/uso terapéutico , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Cadenas Pesadas de Inmunoglobulina/efectos de los fármacos , Cadenas Pesadas de Inmunoglobulina/genética , Cadenas Pesadas de Inmunoglobulina/metabolismo , Región de Unión de la Inmunoglobulina/efectos de los fármacos , Región de Unión de la Inmunoglobulina/metabolismo , Región Variable de Inmunoglobulina/efectos de los fármacos , Región Variable de Inmunoglobulina/metabolismo , Leucocitos/efectos de los fármacos , Leucopenia/inducido químicamente , Leucopenia/tratamiento farmacológico , Linfocitos/metabolismo , Ratones Endogámicos BALB C , Receptores de Antígenos de Linfocitos B/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA